+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Spine Biologics Market By Product: Global Opportunity Analysis and Industry Forecast, 2024-2033

  • PDF Icon

    Report

  • 280 Pages
  • July 2024
  • Region: Global
  • Allied Market Research
  • ID: 5994026
Description Jump to:
The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient’s own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.

Segment Review

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the spinal allografts segment dominated the market in 2023.

As per end user, the hospital segment acquired a high stake in the market in 2023.

Region wise, North America is projected to be the highest revenue generator by 2035.

Competition Analysis

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Spinal Allografts
  • Bone Graft Substitutes
  • Cell-Based Matrix

By End User

  • Hospitals
  • Outpatient Facilities

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Stryker Corporation
  • NuVasive, Inc.
  • orthofix
  • Johnson & Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic plc
  • Organogenesis Inc
  • Kuros Biosciences

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT
4.1. Market Overview
4.1.1 Market Size and Forecast, By Product
4.2. Spinal Allografts
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Bone Graft Substitutes
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Cell-Based Matrix
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Outpatient Facilities
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Product
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Spine Biologics Market
6.2.5.1. Market Size and Forecast, By Product
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Spine Biologics Market
6.2.6.1. Market Size and Forecast, By Product
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Spine Biologics Market
6.2.7.1. Market Size and Forecast, By Product
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Product
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. Germany Spine Biologics Market
6.3.5.1. Market Size and Forecast, By Product
6.3.5.2. Market Size and Forecast, By End User
6.3.6. France Spine Biologics Market
6.3.6.1. Market Size and Forecast, By Product
6.3.6.2. Market Size and Forecast, By End User
6.3.7. UK Spine Biologics Market
6.3.7.1. Market Size and Forecast, By Product
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Italy Spine Biologics Market
6.3.8.1. Market Size and Forecast, By Product
6.3.8.2. Market Size and Forecast, By End User
6.3.9. Spain Spine Biologics Market
6.3.9.1. Market Size and Forecast, By Product
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest Of Europe Spine Biologics Market
6.3.10.1. Market Size and Forecast, By Product
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Product
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. Japan Spine Biologics Market
6.4.5.1. Market Size and Forecast, By Product
6.4.5.2. Market Size and Forecast, By End User
6.4.6. China Spine Biologics Market
6.4.6.1. Market Size and Forecast, By Product
6.4.6.2. Market Size and Forecast, By End User
6.4.7. Australia Spine Biologics Market
6.4.7.1. Market Size and Forecast, By Product
6.4.7.2. Market Size and Forecast, By End User
6.4.8. India Spine Biologics Market
6.4.8.1. Market Size and Forecast, By Product
6.4.8.2. Market Size and Forecast, By End User
6.4.9. South Korea Spine Biologics Market
6.4.9.1. Market Size and Forecast, By Product
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Spine Biologics Market
6.4.10.1. Market Size and Forecast, By Product
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Product
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Spine Biologics Market
6.5.5.1. Market Size and Forecast, By Product
6.5.5.2. Market Size and Forecast, By End User
6.5.6. Saudi Arabia Spine Biologics Market
6.5.6.1. Market Size and Forecast, By Product
6.5.6.2. Market Size and Forecast, By End User
6.5.7. South Africa Spine Biologics Market
6.5.7.1. Market Size and Forecast, By Product
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Spine Biologics Market
6.5.8.1. Market Size and Forecast, By Product
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Stryker Corporation
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. NuVasive, Inc.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Orthofix
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Johnson And Johnson
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Exactech, Inc
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Zimmer Biomet Holding, Inc.
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Arthrex, Inc.
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Medtronic Plc
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Organogenesis Inc
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Kuros Biosciences
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 2. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 6. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. SPINE BIOLOGICS MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. NORTH AMERICA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. NORTH AMERICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 11. NORTH AMERICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 12. U.S. SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 13. U.S. SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 14. CANADA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 15. CANADA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 16. MEXICO SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 17. MEXICO SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 20. EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. GERMANY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 22. GERMANY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. FRANCE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 24. FRANCE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 25. UK SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 26. UK SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. ITALY SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 28. ITALY SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. SPAIN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 30. SPAIN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. REST OF EUROPE SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 32. REST OF EUROPE SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 34. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 35. ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. JAPAN SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 37. JAPAN SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. CHINA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 39. CHINA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. AUSTRALIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 41. AUSTRALIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. INDIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 43. INDIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 44. SOUTH KOREA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 45. SOUTH KOREA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 47. REST OF ASIA-PACIFIC SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. LAMEA SPINE BIOLOGICS MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 49. LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 50. LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. BRAZIL SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 52. BRAZIL SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 54. SAUDI ARABIA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 56. SOUTH AFRICA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 57. REST OF LAMEA SPINE BIOLOGICS MARKET, BY PRODUCT, 2024 - 2033 ($BILLION)
TABLE 58. REST OF LAMEA SPINE BIOLOGICS MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. STRYKER CORPORATION: KEY EXECUTIVES
TABLE 60. STRYKER CORPORATION: COMPANY SNAPSHOT
TABLE 61. STRYKER CORPORATION: OPERATING SEGMENTS
TABLE 62. STRYKER CORPORATION: PRODUCT PORTFOLIO
TABLE 63. STRYKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64. NUVASIVE, INC.: KEY EXECUTIVES
TABLE 65. NUVASIVE, INC.: COMPANY SNAPSHOT
TABLE 66. NUVASIVE, INC.: OPERATING SEGMENTS
TABLE 67. NUVASIVE, INC.: PRODUCT PORTFOLIO
TABLE 68. NUVASIVE, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. ORTHOFIX: KEY EXECUTIVES
TABLE 70. ORTHOFIX: COMPANY SNAPSHOT
TABLE 71. ORTHOFIX: OPERATING SEGMENTS
TABLE 72. ORTHOFIX: PRODUCT PORTFOLIO
TABLE 73. ORTHOFIX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. JOHNSON AND JOHNSON: KEY EXECUTIVES
TABLE 75. JOHNSON AND JOHNSON: COMPANY SNAPSHOT
TABLE 76. JOHNSON AND JOHNSON: OPERATING SEGMENTS
TABLE 77. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
TABLE 78. JOHNSON AND JOHNSON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. EXACTECH, INC: KEY EXECUTIVES
TABLE 80. EXACTECH, INC: COMPANY SNAPSHOT
TABLE 81. EXACTECH, INC: OPERATING SEGMENTS
TABLE 82. EXACTECH, INC: PRODUCT PORTFOLIO
TABLE 83. EXACTECH, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. ZIMMER BIOMET HOLDING, INC.: KEY EXECUTIVES
TABLE 85. ZIMMER BIOMET HOLDING, INC.: COMPANY SNAPSHOT
TABLE 86. ZIMMER BIOMET HOLDING, INC.: OPERATING SEGMENTS
TABLE 87. ZIMMER BIOMET HOLDING, INC.: PRODUCT PORTFOLIO
TABLE 88. ZIMMER BIOMET HOLDING, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. ARTHREX, INC.: KEY EXECUTIVES
TABLE 90. ARTHREX, INC.: COMPANY SNAPSHOT
TABLE 91. ARTHREX, INC.: OPERATING SEGMENTS
TABLE 92. ARTHREX, INC.: PRODUCT PORTFOLIO
TABLE 93. ARTHREX, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 95. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 96. MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 97. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 98. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. ORGANOGENESIS INC: KEY EXECUTIVES
TABLE 100. ORGANOGENESIS INC: COMPANY SNAPSHOT
TABLE 101. ORGANOGENESIS INC: OPERATING SEGMENTS
TABLE 102. ORGANOGENESIS INC: PRODUCT PORTFOLIO
TABLE 103. ORGANOGENESIS INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. KUROS BIOSCIENCES: KEY EXECUTIVES
TABLE 105. KUROS BIOSCIENCES: COMPANY SNAPSHOT
TABLE 106. KUROS BIOSCIENCES: OPERATING SEGMENTS
TABLE 107. KUROS BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 108. KUROS BIOSCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL SPINE BIOLOGICS MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF SPINE BIOLOGICS MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN SPINE BIOLOGICS MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALSPINE BIOLOGICS MARKET
FIGURE 10. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY PRODUCT
FIGURE 11. SPINE BIOLOGICS MARKET FOR SPINAL ALLOGRAFTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. SPINE BIOLOGICS MARKET FOR BONE GRAFT SUBSTITUTES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. SPINE BIOLOGICS MARKET FOR CELL-BASED MATRIX, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL SPINE BIOLOGICS MARKET SEGMENTATION, BY END USER
FIGURE 15. SPINE BIOLOGICS MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. SPINE BIOLOGICS MARKET FOR OUTPATIENT FACILITIES, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 21. COMPETITIVE DASHBOARD
FIGURE 22. COMPETITIVE HEATMAP: SPINE BIOLOGICS MARKET
FIGURE 23. TOP PLAYER POSITIONING, 2023
FIGURE 24. STRYKER CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 25. STRYKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 26. STRYKER CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 27. NUVASIVE, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 28. NUVASIVE, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. NUVASIVE, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. ORTHOFIX: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. ORTHOFIX: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. ORTHOFIX: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. JOHNSON AND JOHNSON: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. JOHNSON AND JOHNSON: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. JOHNSON AND JOHNSON: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. EXACTECH, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. EXACTECH, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. EXACTECH, INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. ZIMMER BIOMET HOLDING, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. ZIMMER BIOMET HOLDING, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. ARTHREX, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. ARTHREX, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. ARTHREX, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. ORGANOGENESIS INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. ORGANOGENESIS INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. ORGANOGENESIS INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. KUROS BIOSCIENCES: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. KUROS BIOSCIENCES: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. KUROS BIOSCIENCES: REVENUE SHARE, BY REGION, 2023 (%)

Companies Mentioned

  • Stryker Corporation
  • NuVasive, Inc.
  • orthofix
  • Johnson & Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic plc
  • Organogenesis Inc
  • Kuros Biosciences

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Related Topics

Related Reports

Spine Biologics Global Market Report 2024 - Product Image

Spine Biologics Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-based Matrix), By End-use (Hospitals, Outpatient Facilities), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Spine Biologics Market Size, Share & Trends Analysis Report By Product (Spinal Allografts, Bone Graft Substitutes, Cell-based Matrix), By End-use (Hospitals, Outpatient Facilities), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From
Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2024-2032 - Product Image

Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Spine Biologic Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Spine Biologic Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Spine Biologics Market by Product (Bone Graft Substitutes, Cell-Base Matrix, Spinal Allografts), Application (Non-Fusion, Spinal Fusion), End-user - Forecast 2024-2030 - Product Image

Global Spine Biologics Market by Product (Bone Graft Substitutes, Cell-Base Matrix, Spinal Allografts), Application (Non-Fusion, Spinal Fusion), End-user - Forecast 2024-2030

  • Report
  • 198 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.